Every letter we have printed

Deamidation is the pathway with the best-characterised kinetics and the least presence in popular discussion, presumably because the product has the same mass. It is invisible to the identity check most people rely on.

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

Single-use indicators are much better than nothing and much weaker than a logger, because they tell you a threshold was crossed and not for how long. Ten minutes above eight degrees on a loading bay and eleven hours in a hot van produce the same red mark.

I disagree with rather more of this than I expected to and I am glad it was printed. An argument I can take issue with is more use than a summary I cannot.

Hydration state, recent exercise and time of day all move these estimates, and serial scans done under different conditions are not comparable. Standardising the conditions is free and it is the single largest improvement available to anybody tracking themselves.

Every method in common use estimates composition from a physical property and a model, and the models were validated in populations that differ from the ones being scanned. The measurement is a calculation and it is reported as an observation.

I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.

As a DXA technologist of twenty-two years I would add one thing to your precision section: the largest source of error in practice is not the machine, it is positioning. A patient scanned with their arms two centimetres further from their trunk will report different regional values. We are trained to a protocol and the protocol is not always followed.

Where an event is described in the literature as rare, it would help enormously to print the actual figure rather than the adjective. Rare means different things in a regulatory glossary and in ordinary speech, and both audiences read the same sentence.

Dehydration is the mechanism by which a manageable symptom becomes a consequential one, and it is worth naming as the link. It is also the point at which renal function becomes the concern rather than the gut.

The mechanistic account is assembled from studies in different species, at different exposures, on different endpoints, and it is presented as one continuous story. Each join in that chain is an inference and none of them is flagged.

A limit expressed in endotoxin units means nothing without a per-kilogram basis and a route, which is where the specification actually lives. Numbers quoted in this market are usually bare figures with no denominator at all.

Water is the usual source. A synthesis and purification chain that uses water of unspecified quality has an endotoxin exposure at every step, and none of it is visible in a purity determination.

A supplier that started publishing this data would differentiate itself immediately, which suggests either that the cost is higher than it appears or that nobody has thought of it. Both are interesting answers.

A publication that keeps naming what is missing is doing something that cannot be done by a certificate, however good. The list of absent tests is editorial work rather than analytical work.

Injecting into an area about to be exercised heavily raises local blood flow and can alter absorption. It is a small effect for weekly molecules and worth a sentence for completeness.

Absorption differs between sites, and for the long-acting molecules discussed here the difference is much less consequential than for rapid-acting insulins. The rotation advice is sound and the reason usually given for it is borrowed from a different drug class.

The number worth asking for is resolving power at the mass you care about, not the headline figure from the brochure. Instruments are specified at a mass convenient to the manufacturer, and a peptide at four thousand daltons is not that mass. Ask where the specification was measured.

For readers who want a rule of thumb: if the report does not state a resolving power, assume it was sufficient to see the molecule and insufficient to see anything close to it. That assumption has been right every time I have been able to check it.

The chromogenic and gel-clot methods report on different scales and are quoted interchangeably. Where a figure appears without the method, it cannot be compared with any other figure.

Environmental monitoring of the filling area is the upstream control that makes a result meaningful, and it is a facility question rather than a batch question. Nobody in this trade publishes anything about their filling environment.

On multiple-dose closures: the puncture budget you refer to is generally in single figures for a standard lyophilisation stopper, and the qualification uses a new needle each time. Anybody reusing a needle through the same entry point is outside the data entirely.

The market has settled on purity because purity is the value a chromatograph produces cheaply. It is a supply-side accident that has become a demand-side expectation, and nobody chose it.

I keep back issues, which I do for no other publication I read, and the reason is that the reference material stays accurate for longer than the news does.

Reporting the number scanned at each timepoint, rather than only at baseline, would let a reader see the attrition directly. It is a single extra row in a table and it is almost never present.

The proportion of loss that is lean tissue is broadly consistent with what is seen in dietary weight loss of similar magnitude, which is the comparison readers need and rarely get. The question is not whether lean mass falls but whether it falls more than it would otherwise.

Protein intake is recorded in some of these trials by food diary, which has a well-characterised and large reporting error. Any analysis conditioning on that variable is conditioning on a noisy estimate and should say so.

Distribution across the day has a modest evidence base and it is a great deal weaker than the total. Presenting the two as equally established is a common error in popular summaries and it displaces attention from the number that matters.

A certificate should say what the sample was when it arrived at the laboratory. Powder, solution, sealed vial, decanted aliquot: each supports a different conclusion, and the analytical section is silent on all of them. The best documents in my file open with a description of the container.

Storage conditions on a certificate should describe what the material was stored under before the determination, not what the buyer ought to do afterwards. The second is advice, the first is data, and the two are printed in the same box.

Your list of absences should include the negative result. Certificates report what was found and not what was looked for and not found. A line stating that no impurity above the reporting threshold was detected other than those listed is a much stronger statement than a table that simply stops.

Sample quantity is a provenance question in disguise. A determination performed on the whole vial and one performed on a few milligrams taken from the top of a settled cake are not equivalent, and neither the amount nor the sampling method appears on any certificate I have collected.

Reading this alongside the issue’s other pieces made the connection between them obvious in a way that neither would have managed alone. The sequencing deserves credit.

Please keep printing the arithmetic. Readers do the sum wrong far more often than they misunderstand the pharmacology, and a worked example with the numbers visible is worth three paragraphs of explanation.

Extending an interval beyond the printed one is the departure nobody objects to and it deserves the same scrutiny as shortening it. A longer interval is safer with respect to tolerability and it also means a longer period at a dose that may not be doing much. There is a cost on both sides.

Confounding by indication is severe in observational work on this class, since the population using these compounds differs systematically from the population not using them. Adjustment helps and does not eliminate it, and the residual should be stated.

The distinction between an expected effect and a serious adverse event is a regulatory one with defined criteria, and general coverage uses the phrase serious as an intensifier. Explaining the formal definition would help readers interpret every safety table they encounter.

Baseline variation in transit time across a healthy population is wide enough to swamp small effects, and studies with modest sample sizes are therefore measuring a difference against a very noisy background. Confidence intervals in this literature are wide for good reasons.

Gastric emptying studies use several different methods and the numbers are not interchangeable. A scintigraphic half-time and a breath-test result answer related questions with different sensitivities, and papers are compared across methods routinely.

The correction printed against an earlier piece in this series was handled better than most publications manage. Owning an error in the same place as the claim is the whole of the practice.